A regulatory perspective on pharmacokinetic/pharmacodynamic modelling
Related Experiment Video
Updated: Oct 18, 2026

An All-Human Hepatic Culture System for Drug Development Applications
Published on: October 20, 2023
1Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20857, USA. machados@cder.fda.gov
Abstract:
We present an integrated summary from statistical and pharmacological perspectives of pharmacokinetic/pharmacodynamic (PK/PD) modelling and its use in drug development and regulation for guiding appropriate dosing. An overview of the technical aspects of PK/PD modelling describes how structural models are constructed and refined using pharmacokinetic and pharmacodynamic principles and how random effects models are used to account for individual differences in desired (and undesired) responses due to patient characteristics. Lastly, we describe applications of PK/PD modelling for the purposes of drug labelling, for resolving a safety concern, and for improving therapeutic monitoring of anaesthetic depth during surgery.
Related Concept Videos
Pharmacokinetic–Pharmacodynamic Relationship: Model Components
Pharmacodynamic Models: Overview
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
